Ignoranti, quem portum petat, nullus suus ventus est.

LUCIUS ANNAEUS SENECA (Minor)

OUR MISSION

Personather was founded in 2015 in order to develop innovative anti-cancer therapies and diagnostic tools, based on personalized medicine. Personather developes absolutely original therapies. Designed by Personather team therapies suppose to target and eliminate only cancer cells. Personather team members have ten years experience in designing anticancer therapies, and twenty years experience in regenerative medicine (stem cells). All projects are implemented by an experienced team of scientists representing many scientific fields (e.g. bioinformatics, molecular and cellular biology, genetic engineering) and using the latest technological achievements.

OUR VISION

DEVELOPMENT OF A THERAPY DESTROYING ONLY CANCER CELLS AND HARMLESS TO NORMAL CELLS
    1. TARGET

    2. INVESTMENT

    3. SCENARIOS

    4. SERVICES

    1. Development of therapies specifically directed against tumor cells is possible if the therapeutic target is present only in cancer cells.

    2. The quick realization of this goal may take place, among others, due to the investment in Personather company and its project (intermediate preclinical trials). One of the project has funding from the NCRD - National Centre for Research and Development.

    3. Implementation of own pre-clinical tests by Personather. Additional projects implementation.

    4. Company carries out service and sales activities. Instant income.

KEY INFORMATION

  • RAPID PROGRESS
  • EXPERIENCE
  • After three years of implementation, Personather has prepared several patent applications for its first project (RASG12V). Personather started three another projects
  • The founders of the company gained experience in other biotech companies which launched over a dozen of biotechnological products, provided services for several entities and has its own production facility. Team has fifteen years experience in stem cells research and twenty years experience in oncology
  • REVENUE
  • KNOW HOW
  • TEAM IP
  • In 2017, 2018 and 2019 Personather achieved services income that enabled to carry out the first NCRD project. In 2019 (JULY) Personather services income is higher than all of 2018. Income after selling technology should be counted in tens of millions
  • Team know how allows to conduct projects and provide services. New projects can be started.
    Stem cells and oncology experience. Biotechnology services experience
  • Co-founders of Personather
    as legal persons own several patents, including the international ones and several patent applications. The company holds shares in one patent applications from outside the NCRD project. Personather applied for SEVERAL independent patents (RAS mutants anticancer therapy) and two utility models

OUR PROJECTS

FUTURE
of the
COMPANY
PERSONATHER IS ABOUT TO DESIGNE ABSOLUTELY ORIGINAL ANTICANCER
THERAPY, OPENING POSSIBILITY TO ENTER CLINICAL TRIAL
  • Subsequent applications for public co-financing (NCRD) of projects concerning
    the development of targeted anti-cancer molecules
  • First technology revenue possible after two years from now
  • Continuation of services for other R&D entities, instant income

MANAGEMENT TEAM

Prof. Piotr Rieske
Chairmam of the board Personather Ltd., CTO, Shareholder

In 2008 prof. Rieske was one of the founders of biotech company Celther Polska Ltd, where he currently helds the CTO position. He participated in several commercializations (stem cells technologies, biodegradable bandage, many scientific research tools). In 2016, he founded the Personather Ltd.
Prof. Piotr Rieske gained his PhD in 1998, two years after getting MSc. He took part in postdoctoral internship at the Thomas Jefferson University, Hahnemann University Hospital and Temple University in Philadelphia. In Poland he was involved in cancer molecular biology research. Since 2012, he is the Chief of Department of Tumor Biology at the Medical University of Lodz. In 2013, he was awarded full professorship.
Prof. Rieske is an author of 66 scientific publications, 4 patents and 17 patent applications (involving seven new anticancer therapies).
Ewelina Stoczynska-Fidelus
PhD, hab.
Shareholder, cellular/molecular biologist

Ewelina graduated from Molecular Genetics at the University of Lodz, Poland and gained her PhD in the Department of Tumor Biology at the Medical University of Lodz, where she currently helds the position of adjunct (associate professor). During her PhD she took part in scientific fellowship at the Temple University in Philadelphia (USA) and was distinguished in the third edition of Polish Scientific Foundation scholarship programme for PhD students.
In 2015, she co-founded Personather Ltd., biotech company, where currently she is a Project Scientific Manager.
Ewelina is the author of 29 scientific publications, 17 patent applications and 4 patents. She specializes in molecular oncology.

SCIENTIFIC TEAM

The team is complemented by specialists in cell, molecular biology and genetic engineering as well as PhD students.
Fifteen employees participated so far in Personather project.

OUR AWARDS

It's our great pleasure and privilege to announce that during the Central European BioForum 2019 Personather received the CEBF Award (Category: Individual Award).

https://www.facebook.com/cebioforum/photos/pcb.2283503015044756/2283497038378687/?type=3&theater

YOU ARE WELCOME TO CONTACT US


phone/fax:
00 48 577 643 986

PERSONATHER Ltd.
R&D Laboratory
Milionowa 23 Street
93-193, Lodz, Poland

e-mail:
terapiacelowana@gmail.com
piotr.rieske@personather.com
office@personather.com
COPYRIGHT
by PERSONATHER 2019